Drug Profile
Trastuzumab biosimilar - BioIntegrator
Alternative Names: BI-MAB-03Latest Information Update: 03 Aug 2022
Price :
$50
*
At a glance
- Originator BioIntegrator
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 03 Aug 2022 Trastuzumab biosimilar is still in preclinical trials for Cancer in Russia (BioIntegrator pipeline, August 2022).
- 28 Nov 2020 No recent reports of development identified for preclinical development in Cancer in Russia
- 28 Oct 2016 Preclinical trials in Cancer in Russia (unspecified route) (BioIntegrator pipeline, October 2016)